Four days left to vote for the top nephrology story of 2013. So far, the top 3 are:
- The CORAL Trial
- The Nephron-D Trial
- JASN paper showing improved mortality for online HDF compared with standard HD.
The first two are not so surprising – high profile papers presented at the ASN and published in the NEJM. Even if they were negative trials, they have a significant impact and will change clinical practice. The third is more surprising to me personally although it is an important paper.
For a round up of pieces promoting various stories in this and other blogs:
- My own take on KIM1 and a piece on the uselessness of urinary eosinophils
- Andrew on UMOD, new targets for PKD and the new cholesterol guidelines
- Paul on Rituximab for ANCA-associated vasculitis
- Edgar on Nephron D at eAJKD
- Matt on APOL1 also at eAJKD
- Kenar at Nephron Power on Abatacept for FSGS
- Ed El Sayed at PBF also on Nephron D
- Joel on Tolvaptan in PKD at PBF
- Christos on HDPAL also at PBF
- Adrian on 23andMe at Red Beans
- Pascale on 23andMe at WhizBANG
Even if you don’t feel like voting, this is a great set of summaries about some of the most important stories in nephrology for the year. Vote early and vote often
